Drug Metabolism: Latest Advances and Prospects

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Pharmacology and Drug Metabolism".

Deadline for manuscript submissions: 30 December 2024 | Viewed by 1489

Special Issue Editors


E-Mail Website
Guest Editor
1. NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, 1099-085 Lisboa, Portugal
2. Research Center for Toxicogenomics and Human Health (ToxOmics), Universidade NOVA de Lisboa, 1099-085 Lisboa, Portugal
Interests: pharmaco-/toxicokinetics; pharmaco-/toxicogenomics; drug metabolism; cytochrome P450; adverse drug reactions (ADRs); drug-induced liver injury (DILI); cancer drug resistance; metabolic liver disease
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. CBIOS, Research Center for Biosciences & Health Technologies, Universidade Lusófona, 1749-024 Lisboa, Portugal
2. ECTS, School of Health Sciences and Technologies, Universidade Lusófona, 1749-024 Lisboa, Portugal
Interests: genetics; clinical biochemistry; genotoxicology; mutagenicity; xenobiotic metabolism; cytochrome P450; in vitro models; pesticides

Special Issue Information

Dear Colleagues,

Drug metabolism, a pivotal process governing the fate of pharmaceutical compounds within the human body, has witnessed remarkable advancements and holds promising prospects in recent scientific exploration. Understanding drug metabolism pathways is crucial for predicting a drug's efficacy, safety, and potential interactions within biological systems.

In recent years, significant strides have been made in elucidating the intricate mechanisms governing drug metabolism. The integration of advanced technologies, such as high-resolution mass spectrometry, computational modeling, and omics approaches, has provided unprecedented insights into metabolic pathways, metabolite identification, and enzyme kinetics.

Moreover, the role of drug metabolism in personalized medicine has garnered substantial attention. The emergence of pharmacogenomics and the identification of genetic variants influencing drug-metabolizing enzymes have revolutionized drug development and patient care. Tailoring treatments based on individual metabolic profiles holds immense promise for optimizing drug efficacy, minimizing adverse reactions, and improving therapeutic outcomes.

The future of drug metabolism research is promising. Advances in artificial intelligence and machine learning algorithms are poised to revolutionize the predictive modeling of drug metabolism, enabling faster and more accurate predictions of metabolic pathways and metabolite profiles for new drug candidates.

Dr. Michel Kranendonk
Dr. Bernardo Brito Palma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • xenobiotic metabolism
  • drug-metabolizing enzymes
  • pharmacokinetics/toxicokinetics
  • pharmacody-namics/toxicodinamics
  • biotransformation
  • metabolomics
  • drug clearance
  • polymophisms
  • metabolic profiling
  • personalized medicine
  • adverse drug reactions (ADRs)
  • drug-induced liver injury (DILI)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 3549 KiB  
Article
Identification and Characterization of Cannabichromene’s Major Metabolite Following Incubation with Human Liver Microsomes
by Alexandra M. Ward, Touraj Shokati, Jost Klawitter, Jelena Klawitter, Vu Nguyen, Laura Kozell, Atheir I. Abbas, David Jones and Uwe Christians
Metabolites 2024, 14(6), 329; https://doi.org/10.3390/metabo14060329 - 13 Jun 2024
Viewed by 1017
Abstract
Cannabichromene (CBC) is a minor cannabinoid within the array of over 120 cannabinoids identified in the Cannabis sativa plant. While CBC does not comprise a significant portion of whole plant material, it is available to the public in a purified and highly concentrated [...] Read more.
Cannabichromene (CBC) is a minor cannabinoid within the array of over 120 cannabinoids identified in the Cannabis sativa plant. While CBC does not comprise a significant portion of whole plant material, it is available to the public in a purified and highly concentrated form. As minor cannabinoids become more popular due to their potential therapeutic properties, it becomes crucial to elucidate their metabolism in humans. Therefore, the goal of this was study to identify the major CBC phase I-oxidized metabolite generated in vitro following incubation with human liver microsomes. The novel metabolite structure was identified as 2′-hydroxycannabicitran using gas chromatography–mass spectrometry and nuclear magnetic resonance spectroscopy. Following the identification, in silico molecular modeling experiments were conducted and predicted 2′-hydroxycannabicitran to fit in the orthosteric site of both the CB1 and CB2 receptors. When tested in vitro utilizing a competitive binding assay, the metabolite did not show significant binding to either the CB1 or CB2 receptors. Further work necessitates the determination of potential activity of CBC and the here-identified phase I metabolite in other non-cannabinoid receptors. Full article
(This article belongs to the Special Issue Drug Metabolism: Latest Advances and Prospects)
Show Figures

Figure 1

Back to TopTop